Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Alan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Keith Johnson and Stephen Gomperts.
Connection Strength

2.314
  1. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol. 2016 Nov 01; 73(11):1334-1341.
    View in: PubMed
    Score: 0.704
  2. 18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. Brain. 2021 02 12; 144(1):266-277.
    View in: PubMed
    Score: 0.237
  3. Topography of cortical thinning in the Lewy body diseases. Neuroimage Clin. 2020; 26:102196.
    View in: PubMed
    Score: 0.220
  4. Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. Neurology. 2019 07 30; 93(5):e476-e484.
    View in: PubMed
    Score: 0.211
  5. PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neurodegener Dis. 2016; 16(1-2):118-24.
    View in: PubMed
    Score: 0.165
  6. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014; 6(5-8):52.
    View in: PubMed
    Score: 0.151
  7. Reply: Beyond the limits of detection: failure of PiB imaging to capture true Aß burden. Mov Disord. 2013 Mar; 28(3):407.
    View in: PubMed
    Score: 0.136
  8. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013 Jan 01; 80(1):85-91.
    View in: PubMed
    Score: 0.134
  9. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012 Jul; 27(8):965-73.
    View in: PubMed
    Score: 0.130
  10. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun. 2017 10 19; 5(1):75.
    View in: PubMed
    Score: 0.047
  11. 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Ann Neurol. 2017 Oct; 82(4):622-634.
    View in: PubMed
    Score: 0.047
  12. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol. 2017 04 01; 74(4):427-436.
    View in: PubMed
    Score: 0.045
  13. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2017 Jan; 81(1):117-128.
    View in: PubMed
    Score: 0.045
  14. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015 Nov; 78(5):787-800.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.